Osteoporosis is a important health concern that leads to significant morbidity for millions of Americans. Most recently, several areas of osteoporosis treatment have been debated, including calcium and vitamin D supplementation, duration of bisphosphonate therapy, and frequency of bone mineral density measurement. This article reviews the recent studies on these controversial topics and presents the current practice guidelines.
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Once osteoporosis has been diagnosed it is classified as either primary or secondary. Primary osteoporosis occurs later in life, in women often following the menopause. Secondary osteoporosis results from medications, concomitant conditions or disease processes 2 (a list of secondary causes can be seen in Table 1 ). 1 These secondary causes must be fully evaluated and excluded prior to initiating treatment. 1 There are several topics for debate in the current treatment of osteoporosis, which will be addressed in this article.
These include the use of calcium and vitamin D supplements, duration of pharmacological therapy, and the appropriate method for monitoring therapy.
Calcium Supplementation
Calcium and vitamin D are important in successful osteoporosis treatment. Randomised clinical trials have demonstrated that adequate calcium intake increased BMD and decreased the incidence of fractures. 3, 4 In these trials, women who received calcium supplements of 1,000-1,200mg/day had fewer fractures than women who did not receive calcium supplementation. Guidelines therefore recommend a daily calcium intake of 800-1,200 mg/day, depending on age group, for adequate bone health. 5 Over the past several years,
however, research studies have demonstrated a possible link between calcium supplementation and increased risk of cardiovascular disease, 6 making the choice of an appropriate dose of calcium the subject of increasing controversy.
In a randomised controlled trial designed to evaluate the effect of calcium supplementation on the risk of cardiovascular disease, 1,471 postmenopausal women were recruited and randomized to receive either 1,000 mg elemental calcium or placebo. After five years of follow-up, the women randomized to calcium were found to have a statistically significant (p=0.0099) increased incidence of myocardial infarction (MI). 7 Following the results of this study, a meta-analysis was performed to evaluate the risk of calcium supplements on cardiovascular events. 8 It included 15 studies in which patients received >500 mg calcium per day. The mean calcium intake was 1,800 mg/day, patients were followed for a minimum of two years, and mean follow-up was 45 months. 
versus placebo. Cardiovascular outcomes were followed as a secondary endpoint. After seven years of follow-up, there was no difference in the number of myocardial infarctions or cerebrovascular events between the groups. 10 This study has been criticised for several reasons: only 50 % of women in the treatment group were taking more than 80 % of the calcium prescribed, and 46 % of the women were already taking calcium supplements prior to randomisation, which may account for the lack of difference at the end of the study. When the study data were re-evaluated, excluding the 46 % of women taking calcium prior to randomisation, there was a statistically significant (p=0.05) increase in clinical MI/stroke in the calcium group. 9 This analysis is limited by the low incidence of cardiovascular events in the WHI trial and by statistically meaningful differences in the baseline characteristics of the members in the placebo and calcium supplementation groups. 9 In the randomised, controlled Calcium intake fracture outcome study (CAIFOS) involving 1,460 women, patients were randomised to calcium carbonate 1,200 mg/day or placebo for five years with observational follow-up for an additional 4.5 years. 8 These patients
were evaluated for atherosclerotic vascular mortality or time of first hospitalisation for a cardiovascular event. No differences were found between the calcium and placebo groups. In addition, there were no differences in the incidence of MI in the two groups. 8 The debate over the effect of calcium on cardiovascular disease remains: currently there are insufficient data on the harm of calcium supplementation to change the daily allowances recommended by the Institute of Medicine (IOM), which are shown in Table 2 . 5 Patients
should not receive more than the recommended daily dose, which means that doctors should ask patients about their dietary intake prior to recommending calcium supplementation.
Vitamin D Supplementation
Vitamin D insufficiency has become an increasingly common problem due to lack of exposure to sunlight and lack of dietary sources rich in vitamin D. Currently, 41 % of men and 52 % of women in the US are vitamin D deficient. 11 Previously, insufficiency had been defined as 25-hydroxyvitamin D (25(OH)D) <30 ng/ml, because this is the level that is associated with maximal suppression of parathyroid hormone (PTH). 12 However, in the recent IOM report on dietary reference intakes for calcium and vitamin D, the committee determined that 20 ng/ml is sufficient for 97.5 % of the population, and that levels above 50 ng/ml may have adverse effects. 5 The report also states that 600 IU/day of vitamin D is sufficient to enable the general population to reach the goal of 20 ng/ml (the IOM's recommendations are shown in Table 3 ). Ross, et al., 2011. 5 Recent Management Controversies in Osteoporosis 
Duration of Pharmacologic Therapy
Pharmacologic therapy is recommended for patients with a history of hip or spine fracture and a BMD of 2.5 SDs below the young adult Research (ASBMR) (see Table 4 ).
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Since the publication of these initial case series involving atypical fractures, several larger studies have reviewed data on such fractures.
A registry-based, cross-sectional study did not find an increased incidence of fractures in patients receiving alendronate. 20 In addition, a secondary analysis was performed of three large, randomised occured in patients on bisphosphonate therapy, equivalent to an absolute risk of 0.0005 or an incidence of five per 10,000 patient years. 22 This supports the findings of low incidence rates for atypical fractures in the randomised bisphosphonate trials, and confirms that the absolute risk of atypical fractures is small compared with the high risk of osteoporotic fractures if patients are not treated. In addition, the task force of the ASBMR did not find any data to support a causal relationship between bisphosphonate therapy and atypical fractures. 19 The Swedish population-based study did demonstrate an increased risk of atypical fracture with duration of bisphosphonate use (odds ratio 1.3 per 100 prescribed daily doses), 22 indicating that it is reasonable to limit the duration of bisphosphonate therapy. The task force of the ASBMR reviewed the literature and found that atypical fractures occur after a median length of treatment with bisphosphonates of seven years. The task force recommends continuing therapy for five years and then determining the need for further therapy on a yearly basis according to the clinical scenario. It is reasonable to consider a holiday from bisphosphonates after five years of treatment, but currently there are no data indicating a decrease in atypical fractures for these patients. 20 The AACE recommends considering a one-to two-year drug holiday after four to five years of treatment with alendronate in patients with mild • Use of pharmaceutical agents (BPs, PPIs, GCs) BPs = bisphosphonates; GCs = glucocorticoids; PPIs = proton pump inhibitors. Source: Shane, et al., 2010. 19 Osteoporosis
osteoporosis. During this holiday, bone turnover markers and DXA scans should be monitored and drug therapy restarted when bone loss is detected. In patients at high risk of fractures, a one-to twoyear drug holiday should be considered after 10 years of treatment.
During the drug holiday, high risk patients may benefit from treatment with teriparatide or raloxifene.
1
Monitoring Therapy
Osteoporosis is in part defined by low bone mass, as measured by DXA scan. The measurement of BMD also can be used to determine the need for pharmacological therapy; however, once patients are started on pharmacological therapy, the need for follow-up DXA scans is not clearly established. A secondary analysis of data from FIT -a randomised, controlled trial evaluating the fracture benefit of alendronate therapy -was conducted to determine the need for maintenance DXA. 22 Patients underwent baseline DXA and yearly follow-up measurements to monitor the effects of therapy. These serial measurements were made with the same type of machine at all the clinical centers. The secondary analysis used a series of mixed models to determine the benefit of serial DXA scans. The study found a BMD increase of more than 0.019 g/cm 2 in 97. colleague's final conclusion is that routine DXA screening is not essential to document increased BMD but to identify the subset of patients with declining BMD on therapy in order that the causes of this decline can be identified. 23 The AACE recommends baseline and repeat DXA scans every one to two years until findings are stable and then follow-up scans every two years. These scans should be performed at the same facility, using the same machine and, if possible, the same technician, to decrease technical variability. To determine if there has been a change in BMD, the testing facility calculates the least significant change (LSC), which is determined by the facilities' technologists after performing a precision analysis, and set at 95 % confidence interval for change.
Conclusion
Osteoporosis is a significant health concern that needs to be appropriately evaluated and treated to prevent morbidity and 
